Andrew Addison, The Addison Report, Franklin, Mass. likes Cordis (OTC, CORD, low $20s ) a maker of angiographic catheters and related products, and neuroscience devices.
"Demand for Cordis' cardiac catheterization products is exploding. Heavy R&D spending and increased marketing expenses have penalized earnings growth. Taking these expenses now, Cordis should reap tremendous dividends in the future. . . . This year's growth rate should increase to 65 percent, with net expected to surge to $1.25."
Thomas Serzan, Gruntal & Co. recommends Florida Progress (NYSE, FPC, high $30s) for investors seeking shelter from recession.
"The company's core electric business is comprised primarily of residential and commercial customer sales, which are less susceptible to fluctuations in business activity than industrial customer sales. In addition, the economy is still expanding as migration to the Sun Belt continues . . . sales are forecast to increase at a 3-4 percent rate over the next several years."
Sy Harding, Investor Forecasts, Palm Coast, Fla., likes Sensormatic (OTC, SNSR, around $14).
"Sensormatic designs and manufactures electronic tags and closed circuit TV systems that deter shoplifting. Growth has been exceptional. With retailers in a profit squeeze, the company is experiencing a further pickup in its business. Reducing losses from thefts is one of the surest ways for retailers to cut costs. Earnings for the latest quarter rose 21 percent. Sales also rose 21 percent. At current levels, we rate the stock a buy."
The Zweig Performance Ratings Report, Bellmore, N.Y. recommends Abbott Laboratories (NYSE, ABT, around $40).
"Abbott is a major health care concern engaged in the development and manufacturing of pharmaceuticals, infant formulas, medical supplies, and diagnostics. The company's ambitious research program has allowed it to enjoy a strong record of sales and earnings growth without having to resort to acquisitions . . . the company is conservatively financed, with debt less than 5 percent of capital."